Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Blood Cancer J. 2023 Sep 27;13(1):152. doi: 10.1038/s41408-023-00923-6.
Blood Cancer J. 2023.
PMID: 37752114
Free PMC article.
No abstract available.
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P.
Martin T, et al. Among authors: casca f.
Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8.
Blood Cancer J. 2023.
PMID: 37156782
Free PMC article.
Clinical Trial.
Item in Clipboard
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchauspé M, Casca F, Macé S, Van de Velde H, Suzuki K.
Martin T, et al. Among authors: casca f.
Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.
Haematologica. 2022.
PMID: 35734925
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite